Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CL-NK-003
- Development stage
- Phase 1
- Lead developer
- Changhai Hospital
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CL-NK-003 is an investigational chimeric antigen receptor (CAR) natural killer (NK) cell therapy developed by Changhai Hospital (First Affiliated Hospital of the Naval Medical University) for the treatment of advanced pancreatic cancer. The therapy utilizes NK cells engineered to target Early Growth Response 1 (EGR1), a transcription factor that is overexpressed in pancreatic cancer and plays a critical role in promoting epithelial-mesenchymal transition (EMT), tumor invasion, and metastasis. CL-NK-003 is designed to recognize and eliminate pancreatic cancer cells that exhibit membrane-positive expression of EGR1. It is currently being evaluated in a Phase 1 first-in-human clinical trial (NCT07425483) to assess its safety, tolerability, and preliminary efficacy in patients with locally advanced, metastatic, or recurrent pancreatic cancer.
- Other names
- CAR-NK Cells (CL-NK-003)
Beyond the preview
Go deeper on CL-NK-003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CL-NK-003.